These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29660005)

  • 21. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
    Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
    Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
    Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
    Chang K; Zhang B; Guo X; Zong M; Rahman R; Sanchez D; Winder N; Reardon DA; Zhao B; Wen PY; Huang RY
    Neuro Oncol; 2016 Dec; 18(12):1680-1687. PubMed ID: 27257279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
    Cloughesy TF; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Ping J; Holland J; Weitzman R; Wen PY
    Neuro Oncol; 2018 Jan; 20(2):259-267. PubMed ID: 29036345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma.
    Ellingson BM; Nguyen HN; Lai A; Nechifor RE; Zaw O; Pope WB; Yong WH; Nghiemphu PL; Liau LM; Cloughesy TF
    Cancer; 2016 Jun; 122(11):1718-27. PubMed ID: 26998740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
    Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
    Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
    Ellingson BM; Abrey LE; Nelson SJ; Kaufmann TJ; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Butowski N; Ligon KL; Gerstner ER; Colman H; de Groot J; Chang S; Mellinghoff I; Young RJ; Alexander BM; Colen R; Taylor JW; Arrillaga-Romany I; Mehta A; Huang RY; Pope WB; Reardon D; Batchelor T; Prados M; Galanis E; Wen PY; Cloughesy TF
    Neuro Oncol; 2018 Aug; 20(9):1240-1250. PubMed ID: 29660006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative Two-Dimensional Size of Glioblastoma is Associated with Patient Survival.
    Leu S; Boulay JL; Thommen S; Bucher HC; Stippich C; Mariani L; Bink A
    World Neurosurg; 2018 Jul; 115():e448-e463. PubMed ID: 29678715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI.
    Lescher S; Jurcoane A; Veit A; Bähr O; Deichmann R; Hattingen E
    Neuroradiology; 2015 Jan; 57(1):11-20. PubMed ID: 25287076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
    Batchelor TT; Mulholland P; Neyns B; Nabors LB; Campone M; Wick A; Mason W; Mikkelsen T; Phuphanich S; Ashby LS; Degroot J; Gattamaneni R; Cher L; Rosenthal M; Payer F; Jürgensmeier JM; Jain RK; Sorensen AG; Xu J; Liu Q; van den Bent M
    J Clin Oncol; 2013 Sep; 31(26):3212-8. PubMed ID: 23940216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
    Hutterer M; Nowosielski M; Haybaeck J; Embacher S; Stockhammer F; Gotwald T; Holzner B; Capper D; Preusser M; Marosi C; Oberndorfer S; Moik M; Buchroithner J; Seiz M; Tuettenberg J; Herrlinger U; Wick A; Vajkoczy P; Stockhammer G
    Neuro Oncol; 2014 Jan; 16(1):92-102. PubMed ID: 24311637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.